Physician profile
Lama Hashish
NPI 1356432389
$11,923.02
in general payments reported to CMS, 2019-2025
40 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,440 · 2020: $1,407 · 2021: $1,511 · 2022: $1,469 · 2023: $1,942 · 2024: $1,692 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,899.67 |
| Education | $196.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,979.61 | 2019-2025 | |
| Amgen INC. | $1,891.20 | 2019-2025 | Enbrel, Krystexxa, Otezla |
| Ucb, INC. | $1,516.29 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $1,031.99 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $855.75 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $717.49 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $421.51 | 2019-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $344.55 | 2020-2025 | Acthar |
| Lilly USA, LLC | $327.31 | 2019-2023 | Taltz |
| Pfizer INC. | $304.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.37 | 2019-2024 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $172.57 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $171.47 | 2023-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $163.70 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $162.89 | 2021-2023 | Saphnelo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $156.46 | 2019 | |
| Depuy Synthes Sales INC. | $150.41 | 2019-2025 | Monovisc, Orthovisc |
| Argenx US, INC. | $137.26 | 2025 | Vyvgart Hytrulo |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Fresenius Kabi USA, LLC | $106.82 | 2023-2024 | Idacio |
| Celgene Corporation | $104.09 | 2024 | |
| Octapharma USA, INC. | $90.00 | 2022-2025 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $86.16 | 2020-2025 | Jubbonti, Hyrimoz |
| Genentech USA, INC. | $82.95 | 2019-2022 | |
| Bioventus LLC | $74.80 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $58.16 | 2019-2022 | |
| Fidia Pharma USA INC. | $55.14 | 2021-2025 | Triluron, Hymovis |
| Celltrion USA INC. | $54.11 | 2023 | Yuflyma |
| Boston Scientific Corporation | $41.83 | 2019 | |
| Organon LLC | $37.57 | 2023 | Hadlima |
| Ultragenyx Pharmaceutical INC. | $31.18 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $29.99 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $28.04 | 2024 | Lupkynis |
| Zyla Life Sciences, INC. | $23.76 | 2020 | |
| Medtronic, INC. | $21.74 | 2023 | Intellis Adaptivestim |
| Tersera Therapeutics LLC | $19.14 | 2022 | |
| Genzyme Corporation | $18.20 | 2019 | |
| Medexus Pharma, INC. | $15.46 | 2019 | |
| Tonix Medicines, INC. | $15.16 | 2025 | Tonmya |
| Antares Pharma, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lama Hashish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.